חטיבת טכנולוגיות רפואיות, מידע ומחקר **המכון לביקורת ותקנים של חומרי רפואה** The Institute for Standardization and Control of Pharmaceuticals



Certificate No: GMP 230/12

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with the requirements of Good Manufacturing Practice, of the Israeli laws and regulations (Pharmacist Regulations [Good Manufacturing Practice for Medicinal Products] 2008)

and

Issued under the provisions of the Conformity Assessment and Acceptance of Industrial Products (CAA) Agreement between the European Union and Israel

The competent authority of Israel confirms the following:

The manufacturer Isotopia Molecular Imaging Ltd.

Site address Soreq Nuclear Research Center, Yavne, 81800, Israel

Has been inspected under the Israeli inspection programme, in connection with manufacturing authorization no. MIA 230, in accordance with the above mentioned laws and regulations

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **18-22 February 2024**, it is considered that it complies with the Good Manufacturing Practice requirements referred to in the Conformity Assessment and Acceptance of Industrial Products (CAA) Agreement between the European Union & Israel and the above mentioned Israeli laws & regulations (*).

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than **three years** have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please contact the issuing authority.

(*) these requirements fulfill the GMP recommendations of WHO

מיכאל כרמי ע. מפקח ארצי תנאי יצור נאותים

GOV. INSTITUTE

CONTROL AND STANDARD
OF
PHARMACEUTICALS

GMP 230/12

page 1 of 4

חטיבת טכנולוגיות רפואיות. מידע ומחקר המכון לביהורת ותהנים של חומרי רפואה The Institute for Standardization and Control of Pharmaceuticals

Part 2

HUMAN MEDICINAL PRODUCTS


1. MANUFACTURING OPERATIONS - MEDICINAL PRODUCTS

- 1.1 Sterile products
 - 1.1.1 Aseptically prepared
 - 1.1.1.2 Lyophilizates
 - 1.1.1.4 Small volume liquids
 - 1.1.1.6 Other aseptically prepared products
 - 1.1.2 Terminally sterilized
 - 1.1.2.3 Small volume liquids
 - 1.1.3 Batch certification

1.5

Packaging

- 1.5.1 Primary packing
- 1.5.2 Secondary packing
- 1.6 Quality control testing
 - 1.6.1 Microbiological: sterility
 - 1.6.2 Microbiological: non-sterility
 - 1.6.3 Chemical/Physical
 - 1.6.4 Biological



20.10.2

מיכאל כרמי ע. מפקח ארצי תנאי יצור נאותים

Any restrictions or clarifying remarks related to the medicinal products

None

GMP 230/12

page 2 of 4

חטיבת טכנולוגיות רפואיות, מידע ומחקר המכו**ן לביקורת ותקנים של חומרי רפואה** The Institute for Standardization and Control of Pharmaceuticals



Part 2

HUMAN INVESTIGATIONAL MEDICINAL PRODUCTS

- 1. MANUFACTURING OPERATIONS INVESTIGATIONAL MEDICINAL PRODUCTS
 - 1.1 Sterile products
 - 1.1.1 Aseptically prepared
 - 1.1.1.2 Lyophilizates
 - 1.1.1.4 Small volume liquids

Any restrictions or clarifying remarks related to the investigational medicinal products

This certificate pertains to the following IMPs (both of them are for Phase III clinical trials):

- Sterile Hydrogel for UGN-102. This product is manufactured under a contractual agreement with Urogen Pharma Ltd
- •ELGN-2112, oral formulation of recombinant human insulin under clinical development to stimulate the development of extremely low gestational age newborns (born more than 3 months before term). This product is manufactured under a contractual agreement with Elgan Pharma Ltd

IMPs for phase III clinical studies are periodically inspected and approved under the national inspection programme

IMPs for phases I, II, are not inspected under this programme. Their production is permitted after ensuring that they do not pose risk of contamination to other products

IMPs are not included in the ACAA between the EU and Israel

O, IPIL

ע. מפקח ארצי תנאי יצור נאותים

OF PHARMACEUTICALS

GMP 230/12

page 3 of 4

משרד הבריאות

חטיבת טכנולוניות רפואיות, מידע ומחקר <mark>המכון לביקורת ותקנים של חומרי רפואה</mark> The Institute for Standardization and Control of Pharmaceuticals

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

3.1 Manufacture of active substances by chemical synthesis

3.1.4 Other Lyophilization of active substances (under contractual agreements with other parties)

Any restrictions or clarifying remarks related to the active substances

The plant is authorized to perform lyophilization of active substance and inert matrixes (vehicles) as a contract agent of other parties

Any restrictions or clarifying remarks related to the scope of this certificate

The main activity on site is the manufacture of sterile medicinal products, by aseptic processing and terminal sterilization.

The plant is also authorized to perform lyophilization of active substance and inert matrixes (vehicles) as a contract agent of other parties.

Name and signature of the authorized person of the Competent Authority of Israel

Michael Carmi, Pharmacist, GMP Inspector

Email: michael.carmi@moh.gov.il

Phone: office 972 -2-6551795, cell 972-50-6242452

GMP 230/12

page 4 of 4

20.10.2

CONTROL AND STANDARD

ע. מפקח ארצי תנאי יצור נאותים